Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, Hyeyoon | - |
dc.contributor.author | Jung, Woon Yong | - |
dc.contributor.author | Kang, Youngran | - |
dc.contributor.author | Lee, Hyunjoo | - |
dc.contributor.author | Kim, Aeree | - |
dc.contributor.author | Kim, Han Kyeom | - |
dc.contributor.author | Shin, Bong Kyung | - |
dc.contributor.author | Kim, Baek-Hui | - |
dc.date.accessioned | 2022-07-14T23:50:44Z | - |
dc.date.available | 2022-07-14T23:50:44Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2016-12 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/153313 | - |
dc.description.abstract | Gastric adenocarcinoma is one of the most common causes of cancer-related death. In this study, we conducted immunohistochemical studies for PD-L1, PD-1, CTLA-4, and CD8 using tissue microarrays from 464 gastric cancer samples and evaluated the correlations between their expression, clinicopathologic factors, and five-year overall survival. PD-L1 and PD-1 expression was significantly correlated with several adverse prognostic pathologic factors, including higher T-stage, diffuse Lauren histologic type, and lymphatic invasion. Conversely, CTLA-4 expression was correlated with factors of favorable clinical outcomes. A complete case analysis revealed that high PD-L1 and PD-1 expression had an adverse effect on five-year overall survival in univariate analyses. Subgroup analyses wherein patients were divided into two groups according to CD8+ tumor infiltrating lymphocyte levels (high and low) showed that high PD-L1 expression was a significant adverse prognostic factor only in the high CD8+ tumor-infiltrating lymphocytes group. Further research and clinical trials are needed to determine the clinical usefulness of these findings. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.title | Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, Woon Yong | - |
dc.identifier.doi | 10.18632/oncotarget.12603 | - |
dc.identifier.scopusid | 2-s2.0-85001114581 | - |
dc.identifier.wosid | 000389877500031 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.7, no.49, pp.80426 - 80434 | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 7 | - |
dc.citation.number | 49 | - |
dc.citation.startPage | 80426 | - |
dc.citation.endPage | 80434 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordPlus | PD-1 | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | CTLA-4 | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordAuthor | gastric adenocarcinoma | - |
dc.subject.keywordAuthor | PD-1 | - |
dc.subject.keywordAuthor | PD-L1 | - |
dc.subject.keywordAuthor | CTLA-4 | - |
dc.subject.keywordAuthor | prognosis | - |
dc.identifier.url | https://www.oncotarget.com/article/12603/text/ | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.